Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 16, 2025

To whom it may concern:

TOWA PHARMACEUTICAL CO., LTD.

# Notice of a Fire at Part of the First Solid Dosage Building at Our Yamagata Plant (Second Report)

At around 7:58 a.m. Monday, July 14, 2025, a fire broke out at part of the First Solid Dosage Building (machine room) at our Yamagata Plant. We deeply apologize for the significant inconvenience and concern caused to our neighbors and all parties involved.

We would like to inform you of the information as of 1:00 p.m. on Wednesday, July 16, 2025 as follows. (Changes are underlined.)

## 1. Date and time

Fire outbreak: At around 7:58 a.m. Monday, July 14, 2025, a fire alarm was triggered. Fire extinguished: At around 12:03 p.m. (noon) Monday, July 14, 2025, the fire department declared the fire extinguished.

#### 2. Location

17-8, Aza Yuzakayama, Kanakame, Kaminoyama, Yamagata The First Solid Dosage Building (machine room) at Towa Pharmaceutical's Yamagata Plant

## 3. Damage situation

There were no injuries.

The only material damage was to one dust collector in the machine room of the First Solid Dosage Building.

### 4. Cause

We conducted an on-site investigation with the fire department and confirmed that smoke was coming from <u>a dust collector</u> in the machine room. We will continue to work with the relevant authorities to quickly determine the cause and take appropriate measures.

## 5. Impact on production and shipment

There is no impact on the production and shipment of the Second and Third Solid Dosage
Buildings. From the evening to the night of Tuesday, July 15, 2025, the packaging process of the
First Solid Dosage Building resumed operations. In addition, other processes are gradually being resumed as well.

#### 6. Impact on business performance

The impact of this fire on our business performance is currently under review.

If any significant impact on performance is expected and matters requiring disclosure arise, we will promptly inform you.